AAP News Vol. 2 No. 9 September 1986, p. 3
© 1986 American Academy of Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

 Previous Article  |  Next Article 

Physician announces breakthrough in Kawasaki Syndrome

A breakthrough in the treatment of Kawasaki Syndrome, an acute childhood illness of unknown cause, was announced last month by Stanford T. Shulman, M.D., FAAP, at Children's Memorial Hospital, Chicago.

Dr. Shulman announced that, when administered early in treatment, high-dose intravenous gamma globulin is safe and effective in reducing the incidence of coronary artery abnormalities, which sometimes occur as a result of Kawasaki Syndrome.